Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Oblomov who wrote (100454)	8/6/2009 10:29:19 AM
From: pogohere	1 Recommendation Read Replies (1) \| Respond to of 116555

Why not just let big pharma just buy the FDA and eliminate the bottleneck?

To: Oblomov who wrote (100454)	8/6/2009 10:37:15 AM
From: Metacomet	Respond to of 116555

We should let the doctor use third party research to make decisions about efficacy. But how would that square with the TV ads that tell you which prescriptions you should be taking. Just tell your doctor.

To: Oblomov who wrote (100454)	8/6/2009 2:36:51 PM
From: NOW	3 Recommendations Read Replies (2) \| Respond to of 116555

"First, research and development (R&D) is a relatively small part of the budgets of the big drug companies—dwarfed by their vast expenditures on marketing and administration, and smaller even than profits. In fact, year after year, for over two decades, this industry has been far and away the most profitable in the United States. (In 2003, for the first time, the industry lost its first-place position, coming in third, behind "mining, crude oil production," and "commercial banks.") The prices drug companies charge have little relationship to the costs of making the drugs and could be cut dramatically without coming anywhere close to threatening R&D." nybooks.com